NCT07748767
Micro-nanoplastic Exposure and Coronary Microcirculatory Dysfunction as Well as Cardiovascular Outcomes
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 14 words
- Primary endpoints: details revised at 1 of 2 entries
- Start date changed from estimate of Jan 1, 2027 to Sep 8, 2026
- Secondary endpoints: details revised at 1 of 2 entries
- Notable Eligibility criteria expanded, about 19 words
- Secondary endpoints: details revised at 1 of 2 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Baseline Peripheral Circulatory MNPs Concentration(μg/g, particles/ml)
Timeframe: baseline
Coronary Microvascular Function
Timeframe: baseline
Secondary (2)
2 years Follow-up MACE
Baseline Intracoronary MNPs Concentration(μg/g, particles/ml)
Arms and interventions
Micro-nanoplastic Exposure and CVOT
According to the baseline circulating MNPs exposure level of the patients, participants will be categorized into the high-exposure group and low-exposure group using the median value as the cutoff point.
Other: micro-nanoplastic examination
Procedures: Microvascular Function Examination
Sites
1 site in 1 country
- Beijing Anzhen HospitalBeijing, China